Reviva Pharmaceuticals Holdings
0.5870+0.01 (+1.68%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · RVPH · USD
Key Stats
Market Cap
56.55MP/E (TTM)
-Basic EPS (TTM)
-0.64Dividend Yield
0%Recent Filings
8-K
Regains MVLS compliance
Reviva Pharmaceuticals Holdings regained Nasdaq compliance with the $35 million minimum Market Value of Listed Securities requirement, as confirmed on October 14, 2025, after sustaining the threshold for 10 consecutive business days ending October 13. Yet the company remains non-compliant with the $1.00 minimum bid price rule, facing a November 10 deadline to cure. Reviva eyes a reverse stock split but offers no guarantees. Compliance lifts one overhang, but bid price woes persist.
8-K
Bylaws quorum lowered sharply
10-Q
Q2 FY2025 results
Reviva Pharmaceuticals narrowed its Q2 operating loss to $6.1 million from $8.1 million a year earlier, while YTD loss eased to $12.5 million versus $15.3 million, driven by R&D spend dropping 33% y/y to $3.7 million amid clinical trial efficiencies. Diluted EPS improved to $(0.12) from $(0.26) y/y, confirmed against 49.8 million weighted shares with anti-dilutive options and warrants excluded. Cash dipped to $10.4 million from $13.5 million at year-end, with operating cash use at $13.2 million offset by $10.1 million in financing, including a June 2025 public offering for $9.0 million net proceeds; short-term debt stands at $0.1 million with no revolver. No capex disclosed, so FCF not computed. Warrant liabilities fell to $16.7 thousand on fair-value gains. Yet funding needs loom large. Clinical trial delays pose a key risk.
8-K
Brilaroxazine OLE trial succeeds
Reviva Pharmaceuticals announced positive full results from its Phase 3 RECOVER 1-year open-label extension trial on August 14, 2025, showing brilaroxazine sustained broad-spectrum efficacy in schizophrenia patients, with PANSS total score improvements of -18.1 and a 35% discontinuation rate over pooled doses. The company narrowed its Q2 2025 net loss to $6.1 million from $7.9 million year-over-year, bolstered by $10.0 million from a recent equity offering, leaving cash at $10.4 million. Brilaroxazine advances. An FDA meeting looms in Q4 2025, targeting NDA submission by Q2 2026, though RECOVER-2 trial initiation hinges on regulatory feedback.
8-K
Reviva prices $10M offering
Reviva Pharmaceuticals priced a $10 million registered public offering on June 26, 2025, selling 20 million shares at $0.50 each alongside Series C warrants (5-year term) and Series D warrants (12-month term), both exercisable immediately at $0.50. Closing is set for June 27, subject to conditions, with net proceeds of ~$9 million earmarked for R&D and working capital. Yet warrants cap ownership at 4.99% (or 9.99% electable), curbing potential dilution. This bolsters Reviva's pipeline funding amid cash needs.
ARTV
Artiva Biotherapeutics, Inc.
4.39-0.34
DRUG
Bright Minds Biosciences Inc.
53.94-3.52
INVA
Innoviva, Inc.
17.57-0.12
IVA
Inventiva S.A. - American Depos
4.16-1.11
LBRX
LB Pharmaceuticals Inc
15.65-0.92
NERV
Minerva Neurosciences, Inc
4.23-0.37
NRXP
NRX Pharmaceuticals, Inc.
3.05+0.05
RAPP
Rapport Therapeutics, Inc.
27.01-0.38
RVRC
REVIUM RECOVERY INC
0.52+0.00
TBPH
Theravance Biopharma, Inc.
14.17+0.07